Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Cystic fibrosis patients’ vulnerability to COVID-19 infection: Preliminary data ease fears
Key clinical point: Clinicians had been concerned about worse outcomes among individuals with cystic fibrosis (CF).
Major finding: A higher proportion of COVID-19–positive patients than the general CF population included Hispanics (18% vs. 9%), Blacks (7% vs. 5%), and individuals with FEV1 value less than 40% predicted (14% vs. 8%).
Study details: Registry analysis.
Disclosures: Dr. Sanders has no relevant financial disclosures.
Citation:
Sanders DB. NACFC 2020.